Human papillomavirus (human papillomavirus) is a high-risk viral target central to prevention and treatment strategies for HPV-driven disease, especially cervical cancer and other hpv dependent malignancies. Its primary mechanism in this context is as an infectious oncogenic agent that is prevented by hpv vaccination and detected through cervical screening, with hrHPV testing used in cervical samples. The literature also discusses HPV as a possible contributor to esophageal squamous cell carcinoma, although the epidemiologic evidence is heterogeneous. Key facts emphasize that it is a target of vaccination prevention efforts, and recent studies highlight both therapeutic vaccination and novel in silico tools for vaccine design.
Cervical cancer and screening
- HPV is described as the cause of cervical cancer and a focus of vaccination and screening uptake among women presenting for abortion. (PMID:41224642)
- Cervical samples were tested for hrHPV in women attending cervical screening, linking HPV detection to screening programs. (PMID:41830505)
- A multicenter cross-sectional study in China reported overall hrHPV prevalence and HPV16/18 infection outcomes in screened women. (PMID:41830505)
- HPV vaccination was associated with lower HPV16/18 infection, supporting prevention of precancer and cervical cancer. (PMID:41830505)
HPV-dependent malignancies and therapeutic vaccination
- Therapeutic vaccination approaches are being developed against HPV in hpv dependent malignancies. (PMID:41986361)
- A 2026 NPJ Vaccines review summarized the current landscape of therapeutic vaccination for HPV-dependent cancers. (PMID:41986361)
- The virus is explicitly framed as the target underlying therapeutic vaccination strategies for HPV-associated malignancies. (PMID:41986361)
- Prevention efforts rely on vaccination against human papillomavirus, reinforcing its role as a vaccine target. (PMID:41986361)
Esophageal squamous cell carcinoma
- The role of HPV in esophageal squamous cell carcinoma was examined as a possible contributor to disease development. (PMID:42028731)
- A 2026 International Journal of Oncology review noted heterogeneous epidemiological evidence for the HPV-ESCC association. (PMID:42028731)
- Multi-omics approaches were used to assess biomarkers and current evidence related to HPV in ESCC. (PMID:42028731)
- The review focused on detection and mechanistic association rather than definitive causality. (PMID:42028731)